Copay assistance fund status, eligibility, and covered drugs — for patient access and billing teams.
Maximum award Contact TAF · Income ≤400% FPL · Covers drug cost only — administration billed separately
Published terms from the foundation. Per-patient eligibility and amounts are confirmed at application.
L20.0 L20.81 L20.82 L20.83 L20.84 L20.89 L20.9 L30.0 L30.1 L30.8 L30.9Drugs whose J-codes this fund matches. Each links to its billing & coding reference.
Also matches J-codes not yet in our drug library: J0139 J1747 J3245
Fund status changes with donations, often without an announcement — confirm directly with the foundation at 855-845-3663, and check the alternatives below.
Manufacturer copay programs may also apply — see the drug pages: Cimzia, Remicade / biosimilars, Skyrizi (IV induction), Stelara / biosimilars.
Status shown as of each fund's last verification.
As of June 14, 2026, the The Assistance Fund Atopic Dermatitis fund is operating a WAITLIST. Call the foundation to confirm current intake. Verify at time of service: 855-845-3663.
Contact TAF. Covers drug cost only — administration billed separately
Household income must be ≤400% FPL. US resident.
Accepted: commercial, medicare. Not eligible: medicaid.
The foundation's published processing time is 5–10 business days. Renewal: annual reapplication.